Methotrexate has been used for rheumatoid arthritis for many years and is now used extensively as a second-line therapy in doses of 7.5 to 20 mg per week. The drug has several well-recognised serious adverse effects which include myelosuppression, hepatotoxicity, enteritis, nephrotoxicity and embryotoxicity. Pulmonary complications associated with methotrexate are uncommon, and include infections secondary to myelosuppression and methotrexate pneumonitis. These must be differentiated from the pulmonary complications of the underlying disease.

Although formal criteria have been proposed for the diagnosis of methotrexate pneumonitis, confirmation of the diagnosis is difficult and often made retrospectively by exclusion when all microbiological results have returned. While potentially fatal when unrecognised, full recovery usually occurs within two months when methotrexate is withdrawn.

Case summary

A 59-year-old man with a six-year history of sero-positive rheumatoid arthritis commenced methotrexate therapy at a dose of 10 mg per week. He also received folic acid 5 mg per week and diclofenac 75 mg twice daily. He received a total of 40 mg methotrexate before presenting with a one-week history of severe dyspnoea.

On examination there were stigmata of rheumatoid arthritis. He was apyrexial, tachypnoeic and centrally cyanosed with coarse bibasal inspiratory crackles. He was not clubbed. Arterial blood gases (breathing air) were: pH 7.49, PaCO\textsubscript{2} 3.9 kPa, PaO\textsubscript{2} 5.1 kPa, and standard bicarbonate 25 mmol/l. On 40% oxygen his PaO\textsubscript{2} was 14.2 kPa. The white cell count was 11.6 x 10\textsuperscript{9} with a polymorphonuclear leucocytosis but no eosinophilia. The erythrocyte sedimentation rate was 16 mm/h. Rheumatoid factor and IgM and IgG antinuclear antibodies were present. Antinuclear antibodies and viral serology were negative. The chest X-ray initially showed patchy lung shadowing which progressed over the next two weeks to involve the mid and lower zones of both lungs. A chest X-ray performed before starting methotrexate had revealed only some fibrotic changes at the left base. Echocardiography was normal. Pulmonary function tests performed after admission are shown in the table.

Methotrexate was withdrawn immediately and the patient started on oxygen therapy. Fibre-optic bronchoscopy and right lower lobe broncho-alveolar lavage (BAL) revealed no evidence of infection, in particular no Pneumocystis carinii; a cell count was not performed. Histology of transbronchial biopsies revealed mild interstitial fibrosis with thrombosed vessels consistent with either rheumatoid disease or methotrexate pneumonitis.

The patient was treated with intravenous methylprednisolone, 500 mg daily for three days, then prednisolone, 60 mg orally for one month. This was reduced to zero over the next two months. Supplementary oxygen was also required while he was in hospital and for a few weeks after discharge. Twelve weeks after initial presentation he was considerably improved, mobilising without oxygen, and his arterial oxygen saturation was 94%.

Discussion

The aetiology of methotrexate pneumonitis is unclear. It usually occurs in the first months of therapy, as in this case, but the onset may be delayed for years. Risk factors, although not identified in all studies, are thought to include pre-existing lung disease, diabetes mellitus, and use of nonsteroidal anti-inflammatory drugs.

The condition has no pathognomonic clinical, laboratory, or radiological features. The diagnosis should be considered in a patient receiving methotrexate who develops an acute respiratory illness. It is essential to exclude infections as a cause and investigations should include viral serology. BAL is also important as Pneumonitis carinii pneumonia can occur in
rheumatoid patients treated with methotrexate.\textsuperscript{4,5} If the patient's clinical condition permits, histological evidence of interstitial pneumonitis may be sought by lung biopsy. Other possible causes of interstitial lung disease are rheumatoid disease itself and treatment with nonsteroidal anti-inflammatory drugs.\textsuperscript{8}

Suggested criteria\textsuperscript{2} for diagnosis of methotrexate pneumonitis are given in box 1. The reported case fulfilled at least seven criteria. The presence of possible risk factors and his improvement over a few weeks after withdrawal of methotrexate, while diclofenac was continued, also support the diagnosis of methotrexate pneumonitis.

Management of suspected methotrexate pneumonitis includes withdrawing the drug and, most importantly, exclusion of infection. Oxygen is usually required. The value of corticosteroids is uncertain, but they are usually given. In some cases empirical treatment for P carinii pneumonia is appropriate until the results of BAL are available.

The CSM/MCA database, compiled from 'yellow card' reports, contains 29 reports of pneumonitis in patients receiving methotrexate. Other reported respiratory complications include pulmonary fibrosis (11), alveolitis (7), and dyspnoea (5). There are 10 reports of lower respiratory tract infections, including two of P carinii and one of varicella zoster.

The prescribing and monitoring of methotrexate therapy is increasingly being transferred to general practitioners, once patients have been stabilised on therapy by hospital doctors. It is important that doctors who prescribe and monitor methotrexate therapy should be aware of its possible adverse effects. The early recognition of these is important for the complete recovery of the patient. For potentially hazardous drugs such as methotrexate, written and agreed shared care guidelines are an important way of ensuring that they are safely monitored in primary care.

**Keywords:** methotrexate pneumonitis, adverse drug reaction

---

**Criteria for methotrexate pneumonitis**

- acute onset dyspnoea
- fever over 38°C
- tachypnoea \( \geq 28 \) breaths/min
- radiological evidence of pulmonary interstitial or alveolar infiltrates
- white cell count \( \leq 1.5 \times 10^9/l \)
- negative blood and sputum cultures
- pulmonary function tests demonstrating a restrictive defect and reduced diffusion capacity
- admission PaO\(_2\) \(< 7.5\) kPa on air
- biopsy evidence of bronchiolitis or interstitial pneumonitis with giant cells, without evidence of infection

**Definite diagnosis:** \( \geq 6 \) criteria met

**Probable diagnosis:** 5 criteria met

**Possible diagnosis:** 4 criteria met

---

**Learning points**

- it may be difficult to differentiate between complications of the underlying disease and adverse reactions from drugs used in its treatment
- there is often no diagnostic test that proves that a complication is caused by an adverse drug reaction; diagnosis is by exclusion
- prescribers must be aware of the adverse effects of drugs they use, however rare, and be vigilant for them. Early recognition and withdrawal of the offending agent may be vital

---

**Box 2**

usually given. In some cases empirical treatment for P carinii pneumonia is appropriate until the results of BAL are available.

The CSM/MCA database, compiled from 'yellow card' reports, contains 29 reports of pneumonitis in patients receiving methotrexate. Other reported respiratory complications include pulmonary fibrosis (11), alveolitis (7), and dyspnoea (5). There are 10 reports of lower respiratory tract infections, including two of P carinii and one of varicella zoster.

The prescribing and monitoring of methotrexate therapy is increasingly being transferred to general practitioners, once patients have been stabilised on therapy by hospital doctors. It is important that doctors who prescribe and monitor methotrexate therapy should be aware of its possible adverse effects. The early recognition of these is important for the complete recovery of the patient. For potentially hazardous drugs such as methotrexate, written and agreed shared care guidelines are an important way of ensuring that they are safely monitored in primary care.

**Keywords:** methotrexate pneumonitis, adverse drug reaction

---


Methotrexate pneumonitis in a patient with rheumatoid arthritis.

R. Clearkin, P. A. Corris and S. H. Thomas

Postgrad Med J 1997 73: 603-604
doi: 10.1136/pgmj.73.863.603

Updated information and services can be found at:
http://pmj.bmj.com/content/73/863/603.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/